Atea Pharmaceuticals (NASDAQ:AVIR) Releases Quarterly Earnings Results

Atea Pharmaceuticals (NASDAQ:AVIR) released its quarterly earnings results on Wednesday. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.15, FiscalAI reports.

Here are the key takeaways from Atea Pharmaceuticals’ conference call:

• C-BEYOND met its primary and secondary endpoints: bemnifosbuvir/ruzasvir achieved a 93.9% SVR rate versus 94.8% for EPCLUSA, demonstrating statistical non-inferiority in a challenging real-world HCV population. Non-cirrhotic patients received an eight-week regimen versus 12 weeks for EPCLUSA, with comparable safety.
• C-FORWARD is fully enrolled with more than 880 patients, and top-line results are expected in early Q1 2027. Pending positive results, Atea expects to submit a U.S. NDA in Q2 2027, although approval and timing remain uncertain.
• Management believes the regimen’s potential advantages—including shorter treatment duration, limited drug-drug interactions, no food effect, and a protease-inhibitor-free composition—could support uptake in poly-medicated and adherence-challenged patients. Atea projects peak annual U.S. net revenue of more than $700 million and a relatively short path to profitability after a targeted mid-2028 launch.
• Atea initiated a Phase I study of AT-587 for hepatitis E, a disease with no approved therapy, and reported completion of the first cohort. The company is targeting proof-of-concept data in 2027, but the program remains at an early clinical stage.
• Atea ended the quarter with $219.5 million in cash and marketable securities and expects its cash runway to extend through 2027. Spending will remain focused primarily on completing the HCV program, regulatory preparation, commercial readiness, and hepatitis E development.

Atea Pharmaceuticals Stock Up 0.2%

AVIR opened at $5.06 on Thursday. The stock has a market cap of $404.95 million, a PE ratio of -2.40 and a beta of 0.30. Atea Pharmaceuticals has a 52 week low of $2.78 and a 52 week high of $6.45. The business’s fifty day simple moving average is $4.67 and its 200 day simple moving average is $4.91.

Institutional Investors Weigh In On Atea Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Prudential Financial Inc. purchased a new position in shares of Atea Pharmaceuticals during the 2nd quarter valued at about $36,000. BNP Paribas Financial Markets grew its position in Atea Pharmaceuticals by 57.7% during the third quarter. BNP Paribas Financial Markets now owns 19,913 shares of the company’s stock valued at $58,000 after acquiring an additional 7,286 shares during the last quarter. Jump Financial LLC grew its position in Atea Pharmaceuticals by 36.5% during the fourth quarter. Jump Financial LLC now owns 19,113 shares of the company’s stock valued at $68,000 after acquiring an additional 5,106 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Atea Pharmaceuticals during the fourth quarter worth approximately $69,000. Finally, Marshall Wace LLP bought a new stake in Atea Pharmaceuticals in the second quarter worth $90,000. Institutional investors own 86.67% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia.